Print
Email
Print Edition Stories
Following the Clean Energy Council Fellows
MHT's Galen Moore: Hiring trends and opportunities
MHT managing editor Rodney Brown on NECN: 22 tech companies give back to community
A second former CuraGen Corp. executive has gone to the venture capital side. Canaan Partners announced this morning that former CuraGen CEO Tim Shannon, M.D., has joined the firm’s Westport, Conn. office as a venture partner.
Connecticut Innovations announced on Monday that former CuraGen CFO David Wurzer had joined the quasi-public venture capital nonprofit as a managing director.
According to Canaan’s press release, Shannon will support the firm’s current healthcare portfolio companies and identify new investment opportunities.
CuraGen, a Branford, Conn.-based company using genomics to develop drugs, was acquired by Celldex Therapeutics Inc. last quarter for $94.5 million in stock. In 2007,
Swiss drug maker Roche bought CuraGen business unit 454 Life Sciences Corp. for $154.9 million.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
